Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen is a promising company with a positively reviewed gene therapy pipeline aimed at addressing unmet medical needs in the retinal disease space. While there may be a potential delay in their Stargardt program, the company has shown strong results in their Phase 2 trials, with a 31% reduction in lesion area and 27% reduction in EZ loss. With a planned pivotal trial in 2026 and potential expedited approval pathways, Ocugen's stock is positioned for growth in the long term, making it a strong investment opportunity for those interested in the biotech sector.

Bears say

Ocugen is a clinical-stage company with a negative outlook on its stock due to its unproven and untested pipeline and high levels of debt. Despite lowering their 12-month price target to $9.50 per diluted share, the company's lack of revenue and high financial risk raises concerns about their ability to successfully bring their products to market. The potential for unexpected safety issues during clinical trials further adds to the uncertainty and risk associated with investing in Ocugen.

Ocugen, Inc. (OCGN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.